Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014
DUBLIN, April 16, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/9g868h/research_and) has announced the addition of the "Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
With the mushroom growth of world diagnostic imaging equipments and apparatuses, as for X-CT contrast media, iodinated contrast media serving as the main one is witnessing unprecedented development. Iohexol is featured with great security, high contrast ratio, lower osmotic pressure and small toxicity for human bodies etc. has become the best-selling contrast media in international market. The sales amount of all kinds of contrast media across the world has exceeded USD 23 billion in 2013, with growth continued to rise at the rate of 6% to 8%.
In recent two years, as for the drug procurement in 22 cities in China, there were six major varieties of contrast media, namely, iohexol, iopromide, gadopentetate dimeglumine, iopamidol, ioversol and meglumine diatrizoate, of which the former three varieties were listed among the best-selling 200 drugs. Recently, hospitals attached more importance to instrument testing, boosting the development of contrast media market.
According to the procurement of contrast media from sampled hospitals in 16 cities, iohexol and iopromide rank first and second respectively, accounting for 43% and 32% of market shares of CT contrast media respectively in domestic market. As for domestic MRI contrast media, gadopentetate dimeglumine still plays the leading role, accounting for 83% of market shares of MRI contrast media.
At present, Bayer Health Care, GE, Shanghai Bracco Sine Pharmaceutical Corp. Ltd., Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Ltd. and BEILU Pharmaceutical Co., Ltd. dominate domestic contrast media market, they account for over 80% of market shares totally.
In recent two years, domestic hospitals with certain strength put their attention on testing and examining, so they increased investment in imaging equipments, resulting in bringing momentum for the growth of contrast media market. Competition in contrast media market is not too fierce, and overall the market is on the rising trend. With continuous input and perfection of inspection equipments in China's large-scale hospitals, contrast media market will continue go up. In addition, contrast media price is high in terms of retail sales with considerable profits, representing one of motivators for its rapid growth. It is predicted that in the next five years, with people's rising health awareness and increase of medical facilities, domestic contrast media market will maintain stable growth, with annual growth rate registering 20%.
Key Topics Covered:
1. Development Overview of Contrast Media Industry
2. Development Overview of Global Contrast Media Industry
3. Environment Analysis of China's Contrast Media Industry
4. Analysis on China's Contrast Media Industry
5. Competitive Landscape of China's Contrast Media Industry
6. Import and Export Data of Contrast Media Products
7. Domestic Major Contrast Media Manufacturing Enterprises
8. Investment and Development Trend of Contrast Media Industry
- BEILU Pharmaceutical Co., Ltd.
- China Resources Double-crane Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
- Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
- Yangtze River Pharmaceutical Group
For more information visit http://www.researchandmarkets.com/research/9g868h/research_and
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets